Atlanta Journal Constitution: Ointment kills antibiotic-resistant bacteria, promotes wound healing
Drug developed by UC researcher could be effective against 'superbugs'
Research at the University of Cincinnati College of Medicine may have added a weapon to hospitals’ bacteria fighting arsenal.
Using the topical drug called AB569 — a combination of acidified nitrite and ethylenediaminetetraacetic acid — promotes killing of antibiotic-resistant bacteria while enhancing the healing of wounds in a variety of burn injuries, the study found. The study was published in the journal Infection and Immunity.
The Atlanta Journal Constitution published a story on the research by Daniel Hassett, PhD, professor in the Department of Molecular Genetics, Biochemistry and Microbiology at the UC College of Medicine. Hassett patented AB569 in 2018.
Daniel Hassett, PhD, professor in the Department of Molecular Genetics, Biochemistry and Microbiology at the UC College of Medicine/Photo/Colleen Kelley/UC Creative + Brand
His research has found that AB569 kills virtually all pathogenic bacteria tested. Those bacteria are some of the most serious pathogens exhibiting multidrug resistance and enhanced virulence properties, according to the Centers for Disease Control and Prevention.
“Multidrug resistant bacteria, often called ‘superbugs,’ are an ever-burgeoning global health problem,” Hassett said. “As a result, there is a critical need to develop novel and effective antimicrobials for the prevention, treatment and eradication and healing of such wounds that are complicated by the most formidable pathogen of burn patients, known as MDR-PA. Injury severity is predominantly due to potentially lethal sepsis caused by MDR-PA.”
AB569 was first seen as a treatment for antibiotic-resistant organisms that cause pulmonary infections in patients with cystic fibrosis and chronic obstructive pulmonary disease, and many other opportunistic infections. In addition to tackling COPD and cystic fibrosis, AB569 may also be effective in addressing infections related to severe burns, urinary tract disorders, endocarditis and diabetes, Hassett said.
Hassett was also interviewed about this research by WVXU. See that coverage here.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
WLWT: Tips to fight off bad allergy symptoms
April 18, 2024
The University of Cincinnati's Ahmad Sedaghat spoke with WLWT about how Cincinnati's geography tends to make allergy symptoms worse and tips to fight off those symptoms.
Medscape: Skin adverse events rare after immunotherapy to treat...
April 17, 2024
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found skin adverse events were rare following immunotherapy treatments for certain skin cancers.
UC researchers develop new CPAP device
April 17, 2024
Researchers at the University of Cincinnati are developing a VortexPAP machine that takes advantage of vortex airflow technology. A preliminary clinical study with current CPAP users demonstrated that the VortexPAP can deliver the pressure levels that are used in the subjects’ CPAP therapy, but the mask is more comfortable to wear. It has a minimalistic design that is less intrusive and barely touches the patient’s face.